Urinary markers for bladder cancer
Open Access
- 1 July 2013
- journal article
- Published by H1 Connect in F1000Prime Reports
- Vol. 5 (21), 21
- https://doi.org/10.12703/p5-21
Abstract
Bladder cancer has the fifth highest incidence of all malignancies in the United States, with a propensity to recur, requiring lifelong surveillance after diagnosis. Urinary markers of disease have been of extreme interest in this field in an effort to simplify surveillance schedules and improve early detection of tumors. Many markers have been described, but most remain investigational. However, some markers have undergone clinical trials and are approved for clinical use. In this review, urinary markers and their application for screening and surveillance of bladder cancer are discussed.This publication has 62 references indexed in Scilit:
- Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular MarkersEuropean Urology, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- The prognostic value of cytology and fluorescence in situ hybridization in the follow‐up of nonmuscle‐invasive bladder cancer after intravesical Bacillus Calmette‐Guérin therapyInternational Journal of Cancer, 2009
- uCyt+/ImmunoCyt™ in the detection of recurrent urothelial carcinomaCancer, 2006
- The role of urinary cytology for detection of bladder cancerEuropean Journal of Surgical Oncology, 2005
- Survivin, versatile modulation of cell division and apoptosis in cancerOncogene, 2003
- Immunocyt Test Improves the Diagnostic Accuracy of Urinary Cytology: Results of a French Multicenter StudyJournal of Urology, 2003
- Evaluation of urine CYFRA 21‐1 for the detection of primary and recurrent bladder carcinomaCancer, 2002
- The natural history of a T1 bladder cancer: life-long tumour diathesisBJU International, 2001
- Can biological markers replace cystoscopy? An updateCurrent Opinion in Urology, 2001